{"id":"https://openalex.org/W2037536588","doi":"https://doi.org/10.1159/000151415","title":"Effects of Milnacipran and Paroxetine on Overactive Bladder due to Neurologic Diseases: A Urodynamic Assessment","display_name":"Effects of Milnacipran and Paroxetine on Overactive Bladder due to Neurologic Diseases: A Urodynamic Assessment","publication_year":2008,"publication_date":"2008-01-01","ids":{"openalex":"https://openalex.org/W2037536588","doi":"https://doi.org/10.1159/000151415","mag":"2037536588","pmid":"https://pubmed.ncbi.nlm.nih.gov/18931554"},"language":"en","primary_location":{"id":"doi:10.1159/000151415","doi":"https://doi.org/10.1159/000151415","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000151415","pdf_url":null,"source":{"id":"https://openalex.org/S2232815","display_name":"Urologia Internationalis","issn_l":"0042-1138","issn":["0042-1138","1423-0399"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Urologia Internationalis","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5083613523","display_name":"Ryuji Sakakibara","orcid":"https://orcid.org/0000-0002-5803-169X","observed_orcids":["https://orcid.org/0000-0002-5803-169X"]},"institutions":[{"id":"https://openalex.org/I129634264","display_name":"Toho University","ror":"https://ror.org/02hcx7n63","country_code":"JP","type":"education","lineage":["https://openalex.org/I129634264"]},{"id":"https://openalex.org/I4210125448","display_name":"Toho University Medical Center Sakura Hospital","ror":"https://ror.org/02xrm8w90","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210125448"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Ryuji Sakakibara","raw_affiliation_strings":["Division of Neurology, Department of Internal Medicine, Sakura Medical Center, Toho University, Sakura, Japan. sakakibara@sakura.med.toho-u.ac.jp","Departments of","Division of Neurology, Department of Internal Medicine, Sakura Medical Center, Toho University, Sakura"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Division of Neurology, Department of Internal Medicine, Sakura Medical Center, Toho University, Sakura, Japan. sakakibara@sakura.med.toho-u.ac.jp","institution_ids":["https://openalex.org/I129634264","https://openalex.org/I4210125448"]},{"raw_affiliation_string":"Departments of","institution_ids":[]},{"raw_affiliation_string":"Division of Neurology, Department of Internal Medicine, Sakura Medical Center, Toho University, Sakura","institution_ids":["https://openalex.org/I129634264","https://openalex.org/I4210125448"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5069711734","display_name":"Takashi Ito","orcid":"https://orcid.org/0000-0002-1023-587X","observed_orcids":["https://orcid.org/0000-0002-1023-587X"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takashi Ito","raw_affiliation_strings":["Neurology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5049505360","display_name":"Tomoyuki Uchiyama","orcid":"https://orcid.org/0000-0002-5594-5170","observed_orcids":["https://orcid.org/0000-0002-5594-5170"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Tomoyuki Uchiyama","raw_affiliation_strings":["Neurology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083061529","display_name":"Yusuke Awa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I159385669","display_name":"Chiba University","ror":"https://ror.org/01hjzeq58","country_code":"JP","type":"education","lineage":["https://openalex.org/I159385669"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Yusuke Awa","raw_affiliation_strings":["Urology, Chiba University, and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Urology, Chiba University, and","institution_ids":["https://openalex.org/I159385669"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5108460561","display_name":"Chiharu Yamaguchi","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210099339","display_name":"Chiba University Hospital","ror":"https://ror.org/0126xah18","country_code":"JP","type":"healthcare","lineage":["https://openalex.org/I4210099339"]}],"countries":["JP"],"is_corresponding":false,"raw_author_name":"Chiharu Yamaguchi","raw_affiliation_strings":["Central Laboratory Unit, Chiba University Hospital, Chiba, Japan"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Central Laboratory Unit, Chiba University Hospital, Chiba, Japan","institution_ids":["https://openalex.org/I4210099339"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5026139239","display_name":"Takamichi Hattori","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Takamichi Hattori","raw_affiliation_strings":["Neurology and"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurology and","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":4,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":2.4095,"has_fulltext":false,"cited_by_count":34,"citation_normalized_percentile":{"value":0.87868852,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":88,"max":98},"biblio":{"volume":"81","issue":"3","first_page":"335","last_page":"339"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10279","display_name":"Urinary Bladder and Prostate Research","score":0.9994999766349792,"subfield":{"id":"https://openalex.org/subfields/2748","display_name":"Urology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10418","display_name":"Pelvic floor disorders treatments","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2745","display_name":"Rheumatology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11232","display_name":"Urinary Tract Infections Management","score":0.0,"subfield":{"id":"https://openalex.org/subfields/2713","display_name":"Epidemiology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/milnacipran","display_name":"milnacipran","score":0.9229999780654907},{"id":"https://openalex.org/keywords/paroxetine","display_name":"paroxetine","score":1.0},{"id":"https://openalex.org/keywords/overactive-bladder","display_name":"overactive bladder","score":0.9980000257492065},{"id":"https://openalex.org/keywords/neurological-disorders","display_name":"neurological disorders","score":0.9580000042915344},{"id":"https://openalex.org/keywords/serotonin-norepinephrine-reuptake-inhibitors","display_name":"serotonin-norepinephrine reuptake inhibitors","score":0.9449999928474426},{"id":"https://openalex.org/keywords/selective-serotonin-reuptake-inhibitors","display_name":"selective serotonin reuptake inhibitors","score":0.9900000095367432},{"id":"https://openalex.org/keywords/urodynamic-study","display_name":"urodynamic study","score":0.8360000252723694},{"id":"https://openalex.org/keywords/bladder-capacity","display_name":"bladder capacity","score":0.9819999933242798},{"id":"https://openalex.org/keywords/urinary-frequency","display_name":"urinary frequency","score":0.9559999704360962},{"id":"https://openalex.org/keywords/quality-of-life","display_name":"quality of life","score":0.9020000100135803},{"id":"https://openalex.org/keywords/lower-urinary-tract-symptoms","display_name":"lower urinary tract symptoms","score":0.9269999861717224}],"concepts":[{"id":"https://openalex.org/C2780199185","wikidata":"https://www.wikidata.org/wiki/Q421058","display_name":"Milnacipran","level":4,"score":0.9763113260269165},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8595864772796631},{"id":"https://openalex.org/C2777828372","wikidata":"https://www.wikidata.org/wiki/Q408471","display_name":"Paroxetine","level":4,"score":0.6921477913856506},{"id":"https://openalex.org/C2778941218","wikidata":"https://www.wikidata.org/wiki/Q331231","display_name":"Overactive bladder","level":3,"score":0.6651525497436523},{"id":"https://openalex.org/C31487548","wikidata":"https://www.wikidata.org/wiki/Q4859664","display_name":"Reuptake inhibitor","level":4,"score":0.5159950256347656},{"id":"https://openalex.org/C2910564767","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine Hydrochloride","level":4,"score":0.5046762228012085},{"id":"https://openalex.org/C2780764818","wikidata":"https://www.wikidata.org/wiki/Q411932","display_name":"Duloxetine","level":3,"score":0.4453139901161194},{"id":"https://openalex.org/C77411442","wikidata":"https://www.wikidata.org/wiki/Q181100","display_name":"Urinary system","level":2,"score":0.44303229451179504},{"id":"https://openalex.org/C126894567","wikidata":"https://www.wikidata.org/wiki/Q105650","display_name":"Urology","level":1,"score":0.4377315044403076},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.4256933629512787},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40740224719047546},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.3888784348964691},{"id":"https://openalex.org/C2775864247","wikidata":"https://www.wikidata.org/wiki/Q167934","display_name":"Serotonin","level":3,"score":0.34949547052383423},{"id":"https://openalex.org/C2780051608","wikidata":"https://www.wikidata.org/wiki/Q42844","display_name":"Major depressive disorder","level":3,"score":0.11618801951408386},{"id":"https://openalex.org/C2779144063","wikidata":"https://www.wikidata.org/wiki/Q338924","display_name":"Amygdala","level":2,"score":0.0},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000078764","descriptor_name":"Milnacipran","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D001750","descriptor_name":"Urinary Bladder, Neurogenic","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D001750","descriptor_name":"Urinary Bladder, Neurogenic","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D003521","descriptor_name":"Cyclopropanes","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011446","descriptor_name":"Prospective Studies","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011788","descriptor_name":"Quality of Life","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D011795","descriptor_name":"Surveys and Questionnaires","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D014563","descriptor_name":"Urodynamics","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017367","descriptor_name":"Selective Serotonin Reuptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D017374","descriptor_name":"Paroxetine","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D018759","descriptor_name":"Adrenergic Uptake Inhibitors","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018759","descriptor_name":"Adrenergic Uptake Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D053201","descriptor_name":"Urinary Bladder, Overactive","qualifier_ui":"Q000503","qualifier_name":"physiopathology","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1159/000151415","doi":"https://doi.org/10.1159/000151415","is_oa":false,"landing_page_url":"https://doi.org/10.1159/000151415","pdf_url":null,"source":{"id":"https://openalex.org/S2232815","display_name":"Urologia Internationalis","issn_l":"0042-1138","issn":["0042-1138","1423-0399"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2"],"host_organization":"https://openalex.org/P4310317820","host_organization_name":"Karger Publishers","host_organization_lineage":["https://openalex.org/P4310317820"],"host_organization_lineage_names":["Karger Publishers"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Urologia Internationalis","raw_type":"journal-article"},{"id":"pmid:18931554","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/18931554","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Urologia internationalis","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"score":1.0,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":23,"referenced_works":["https://openalex.org/W26646949","https://openalex.org/W160026725","https://openalex.org/W208038569","https://openalex.org/W1514538584","https://openalex.org/W1867335213","https://openalex.org/W1903565452","https://openalex.org/W1965762284","https://openalex.org/W1967107894","https://openalex.org/W1967312126","https://openalex.org/W1968869699","https://openalex.org/W1972167761","https://openalex.org/W1989542911","https://openalex.org/W1999864181","https://openalex.org/W2035387546","https://openalex.org/W2044589919","https://openalex.org/W2067889220","https://openalex.org/W2073732782","https://openalex.org/W2079317245","https://openalex.org/W2083272868","https://openalex.org/W2140064768","https://openalex.org/W2148333114","https://openalex.org/W2184332729","https://openalex.org/W2224510085"],"related_works":["https://openalex.org/W2337928325","https://openalex.org/W4412420845","https://openalex.org/W4398137422","https://openalex.org/W4313312491","https://openalex.org/W3212015874","https://openalex.org/W2780028233","https://openalex.org/W1951892118","https://openalex.org/W1480194032","https://openalex.org/W2078789015","https://openalex.org/W4223462549"],"abstract_inverted_index":{"AIMS:":[0],"To":[1],"determine":[2],"the":[3,68,95,121,153,157,168,186],"effects":[4,181],"of":[5,32,83,88,123,156,175],"milnacipran":[6,69,84],"hydrochloride,":[7,15],"a":[8,16,38,58,99],"serotonin-norepinephrine":[9],"reuptake":[10,19],"inhibitor":[11],"(SNRI),":[12],"or":[13,85,163,166],"paroxetine":[14,74,169],"selective":[17],"serotonin":[18],"inhibitor,":[20],"on":[21],"overactive":[22],"bladder":[23,131,194],"(OAB)":[24],"in":[25,57,144,152,167,198,205],"neurologic":[26,208],"diseases,":[27],"given":[28],"by":[29],"objective":[30],"measures":[31],"urodynamic":[33,103,145,164,199],"studies.":[34,104,146],"METHODS:":[35],"This":[36],"is":[37],"prospective":[39],"open":[40],"trial,":[41],"and":[42,73,91,102,129,201],"we":[43,97],"enrolled":[44],"24":[45],"patients":[46,206],"(16":[47],"men,":[48],"8":[49],"women;":[50],"mean":[51],"age,":[52],"63.9":[53],"years)":[54],"with":[55,80,207],"OAB":[56,204],"neurology":[59],"clinic.":[60],"They":[61],"were":[62,150,182],"randomly":[63],"allocated":[64],"into":[65],"two":[66],"groups:":[67],"group":[70,75],"(11":[71],"patients),":[72],"(13":[76],"patients).":[77],"We":[78],"started":[79],"100":[81],"mg/day":[82,87],"40":[86],"paroxetine.":[89],"Before":[90],"3":[92],"months":[93],"after":[94],"treatment,":[96],"performed":[98],"urinary":[100,109,159],"questionnaire":[101,162],"RESULTS:":[105],"Milnacipran":[106],"reduced":[107],"daytime":[108],"frequency":[110],"(average,":[111,133],"from":[112,134],"9.4":[113],"to":[114,136],"7.1":[115],"times,":[116],"p":[117,139],"<":[118],"0.001),":[119],"improved":[120],"quality":[122],"life":[124],"index":[125],"(p":[126],"=":[127,140],"0.023),":[128],"increased":[130,193],"capacity":[132,195],"289":[135],"377":[137],"ml,":[138],"0.009)":[141],"as":[142,196],"shown":[143,197],"No":[147],"such":[148],"changes":[149],"noted":[151],"other":[154],"categories":[155],"lower":[158],"tract":[160],"symptoms":[161],"studies,":[165,200],"group.":[170],"One":[171],"male":[172],"patient":[173],"complained":[174],"mild":[176],"voiding":[177],"difficulty.":[178],"Other":[179],"adverse":[180,212],"not":[183],"seen":[184],"during":[185],"observation":[187],"period.":[188],"CONCLUSION:":[189],"Milnacipran,":[190],"an":[191],"SNRI,":[192],"thereby":[202],"ameliorated":[203],"diseases":[209],"without":[210],"serious":[211],"effects.":[213]},"counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2023,"cited_by_count":5},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":1},{"year":2019,"cited_by_count":3},{"year":2017,"cited_by_count":2},{"year":2015,"cited_by_count":3},{"year":2014,"cited_by_count":4},{"year":2013,"cited_by_count":2},{"year":2012,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}